Results of VCUART trials with IL-1 blockade with anakinra in patients with acute STEMI showed significant decrease in the systemic inflammatory response and lower incidence of death or new-onset HF or of death and HFH in 12-month follow-up [56]. This evidence concerns the gene IL1A and hydrops fetalis.